Indomotx
9 employees on LinkedIn · 2 known investors
Indomo Tx develops drug delivery technology focused on dermatology and consumer health, aiming to improve patient outcomes by helping individuals manage their own health. It is backed by a team with expertise in drug delivery, dermatology, and clinical and pharmaceutical fields.
Also known as Indomo · Indomo Tx
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Indomo (Indomo Tx) is a dermatology-focused drug delivery company developing what it describes as the first fast-acting at-home solution for inflammatory acne lesions. Its lead program combines a drug candidate, DT-001, with a novel intradermal self-injection device called the ClearPen. The intent is to move a treatment currently performed in a physician's office — intralesional injection for moderate to severe acne lesions — into the hands of patients for self-administration at home.
The approach is based on intralesional triamcinolone acetonide injection, which the company notes is recommended by the American Academy of Dermatology as a first-line treatment for inflammatory lesions and has more than 50 years of real-world clinical experience. Unlike topical products, injected triamcinolone acetonide delivers the drug directly to the site of inflammation. Indomo's device design goal is to let patients control dosage, depth, and volume of injection safely outside a clinical setting.
The company states that its products are under development and have not been evaluated by the FDA or any other regulatory health authority.
Founding story
The company was founded by a team drawn from consumer health and dermatology backgrounds, including a co-founder of Hims & Hers and veterans of Starface, combining expertise in drug delivery, consumer health, dermatology, and acne.
Traction
Indomo has conducted two investigator-led trials comparing provider injection with patient self-injection. In a company-sponsored trial with 56 participants, the company reports zero adverse events, significant improvement of the lesion within 24 hours in over two thirds of participants, and results comparable between clinical and self-injection methods. Data is described as on-file.
Latest developments
The company launched publicly with an investigational at-home injectable acne candidate, drawing coverage from Bloomberg, Business of Fashion, BeautyMatter, Women's Health, Crunchbase News, Dermatology Times, and Women's Wear Daily. Reporting noted the launch involved $25 million and that the founding team includes veterans of Hims & Hers and Starface.
▸Full profile — market position, technology, go-to-market, risks & controversies
Market position
Indomo positions itself as bringing an established in-office dermatological procedure into the at-home consumer setting, with company messaging describing its candidate as the first fast-acting at-home solution for inflammatory acne lesions.
Rather than a topical formulation, Indomo aims to deliver an injectable corticosteroid directly to the inflamed lesion, replicating a physician-administered procedure while allowing patients to self-treat on their own schedule.
Technology
The product is a drug-device combination consisting of DT-001, a drug candidate, and the ClearPen, an intradermal self-injection device. The device is designed to control the dosage, depth, and volume of injection so that patients can replicate an in-office intralesional injection procedure at home. The underlying therapeutic approach uses intralesional triamcinolone acetonide, an injection with over 50 years of real-world clinical use that delivers drug directly to the site of inflammation rather than through the skin surface as topicals do.
Go-to-market
Patients with moderate to severe inflammatory acne lesions who would otherwise need an in-office dermatologist visit to receive an intralesional injection.
Risks & controversies
Indomo's products are investigational and, per the company, have not been evaluated by the FDA or any regulatory health authority, so regulatory clearance for the drug-device combination remains outstanding. Efficacy and safety data cited to date come from company-sponsored or investigator-led studies with data held on file.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsIndomo publicly launched its at-home acne injection brand, pairing drug candidate DT-001 with the ClearPen intradermal self-injection device; coverage cited a $25 million launch amount.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Indomotxindomotx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Indomotx do?
- Indomo is developing an at-home intradermal self-injection drug-device combination for inflammatory acne lesions.
- Who founded Indomotx?
- Indomotx was founded by Rick Bente, Jack Abraham.
- Who are Indomotx's investors?
- Indomotx's investors include Atomic, Evolution VC Partners.